Headquartered in Marietta, Georgia, MiMedx Group, Inc. specializes in advanced regenerative medicine through the processing of human amniotic and placental tissues. The company utilizes its proprietary PURION process to create shelf-stable allografts that retain essential growth factors and regulatory proteins. Its core product portfolio includes EpiFix, used as a barrier membrane for treating chronic wounds like diabetic foot ulcers, and AmnioFix, designed for surgical and orthopedic applications. The company generates revenue primarily through direct sales to healthcare professionals, hospitals, and wound care clinics across the United States, while also maintaining a growing international presence. MiMedx operates distinct Wound Care and Surgical business segments to address unmet clinical needs in tissue repair and regeneration.
